Glenmark Pharmaceuticals Limited
NSE: GLENMARKINE935A01035·HealthcareMidcap 150·www.glenmarkpharma.com ↗·Mcap ₹69,769 Cr·Listed 2000
₹2,380.00▼ ₹50.40  (−2.07%)
52W: ₹1,793 – ₹2,538 · Vol: 7.9L shares · Close 25 Sept
Set Alert

News & Filings

NSE filings · newest first · 2 on record

Wed, 23 Sept, 2026

Press release dated September 23, 2026, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification".
Press releasePress Release08:41 IST PDF 852.67 KB XBRL

Mon, 21 Sept, 2026

Schedule of meet
Investor meetAnalysts/Institutional Investor Meet/Con. Call Updates14:52 IST PDF 3.61 MB XBRL
Source: NSE corporate announcements, as filed by the company. Times are IST. Press coverage is not included yet.
Filing activity · 30 days
2filings · +2 vs the 30 days before
● Investor meets 1● Press & deals 1
NSE filings by type. Press coverage and sentiment are not included yet.
Material vs routine · 90 days
Material events 1 in 90 days
23 SeptPress release Press release dated September 23, 2026, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification". PDF
Routine disclosures 1
investor meets 1
Split by NSE filing category: business events (results, ratings, deals, leadership, capital actions, regulatory) versus schedules, notices and general updates. Not a view on importance.
Corporate Actions
loading…